Citadel Advisors’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Citadel Advisors’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,015	Closed	-$2.93K	–	15492
2023 Q3	$2.93K	Buy	13,015 +860	+7%	+$231	﹤0.01%	13655
2023 Q2	$3.19K	Sell	12,155 -102	-0.8%	-$20	﹤0.01%	13710
2023 Q1	$2.21K	Buy	12,257 +1,469	+14%	+$336	﹤0.01%	14183
2022 Q4	$2.16K	Buy	10,788 +65	+0.6%	+$28	﹤0.01%	14372
2022 Q3	$8K	Sell	10,723 -1,768	-14%	-$1.21K	﹤0.01%	12316
2022 Q2	$7K	Buy	+12,491	New	+$7.92K	﹤0.01%	12650
2021 Q4	–	Sell	-20,059	Closed	-$68K	–	14995
2021 Q3	$68K	Buy	+20,059	New	+$71.4K	﹤0.01%	13178

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Citadel Advisors's DNA.WS Position: Q4 2023 in Review

Citadel Advisors sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q4 2023, closing a stake of 13,015 shares — an estimated $2.93K sold.

Citadel Advisors first reported a position in DNA.WS in Q3 2021 and held it in 7 quarters. The position peaked at $68K in Q3 2021. 34 funds tracked by Wall St. Rank hold DNA.WS as of Q4 2023.

Citadel Advisors reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q4 2023 after selling out during the quarter.
Citadel Advisors sold 13,015 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q4 2023, an estimated $2.93K.
Citadel Advisors first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 7 quarters.
Citadel Advisors's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $68K in Q3 2021.
34 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.